Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | GPR6 | P46095 | 10/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26933439 | 1.00 | GRIN1 (0.47) | GRIN1GRIN2BGPR6OPRM1OPRK1 | |
| SCHEMBL21222680 | 0.85 | PDE4D (0.41) | POLB | |
| SCHEMBL21222678 | 0.85 | PDE4D (0.41) | POLB | |
| SCHEMBL29875175 | 0.82 | KDM4D (0.43) | GRIN1GRIN2BGPR6 | |
| SCHEMBL26933301 | 0.80 | SLC6A2 (0.51) | GRIN1GRIN2B | |
| SCHEMBL26933296 | 0.80 | SLC6A2 (0.51) | GRIN1GRIN2B | |
| SCHEMBL16908826 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9A | |
| SCHEMBL26933174 | 0.79 | PTGS1 (0.39) | GRIN1GRIN2BGPR6POLB | |
| SCHEMBL16908827 | 0.79 | ALDH1A1 (0.42) | NPC1RAB9A | |
| SCHEMBL26933168 | 0.79 | PTGS1 (0.39) | GRIN1GRIN2BGPR6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | GRIN1 489/4885GRIN2B 334/4885GPR6 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.